📊 TARA Key Takeaways
Is Protara Therapeutics, Inc. (TARA) a Good Investment?
Protara is a pre-revenue biopharmaceutical company generating only $178K in annual revenue while burning $56.5M in operating cash annually. With $49.7M in cash and minimal runway, the company faces near-term solvency risk absent successful drug development and capital raises.
Why Buy Protara Therapeutics, Inc. Stock? TARA Key Strengths
- Strong balance sheet with $196.4M stockholders equity and zero debt
- Excellent liquidity with 14.58x current ratio and $49.7M cash position
- No long-term debt obligations limiting financial flexibility
TARA Stock Risks: Protara Therapeutics, Inc. Investment Risks
- Pre-revenue stage with only $178K revenue and 101.2% YoY decline
- Negative $56.5M operating cash flow with less than 1 year cash runway
- Entirely dependent on unproven drug development, clinical trial success, and FDA approval
Key Metrics to Watch
- Monthly cash burn rate and adjusted runway timeline
- Clinical trial progress and regulatory milestone achievements
- Capital raise activities and revenue-generating product development status
Protara Therapeutics, Inc. (TARA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.58x current ratio provides a solid financial cushion.
TARA Profit Margin, ROE & Profitability Analysis
TARA vs Healthcare Sector: How Protara Therapeutics, Inc. Compares
How Protara Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Protara Therapeutics, Inc. Stock Overvalued? TARA Valuation Analysis 2026
Based on fundamental analysis, Protara Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Protara Therapeutics, Inc. Balance Sheet: TARA Debt, Cash & Liquidity
TARA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Protara Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.17 indicates the company is currently unprofitable.
TARA Revenue Growth, EPS Growth & YoY Performance
TARA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2015 | $2.9M | -$5.2M | N/A |
| Q3 2014 | $2.9M | -$2.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Protara Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TARA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Protara Therapeutics, Inc. (CIK: 0001359931)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TARA
What is the AI rating for TARA?
Protara Therapeutics, Inc. (TARA) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TARA's key strengths?
Claude: Strong balance sheet with $196.4M stockholders equity and zero debt. Excellent liquidity with 14.58x current ratio and $49.7M cash position.
What are the risks of investing in TARA?
Claude: Pre-revenue stage with only $178K revenue and 101.2% YoY decline. Negative $56.5M operating cash flow with less than 1 year cash runway.
What is TARA's revenue and growth?
Protara Therapeutics, Inc. reported revenue of $178.0K.
Does TARA pay dividends?
Protara Therapeutics, Inc. does not currently pay dividends.
Where can I find TARA SEC filings?
Official SEC filings for Protara Therapeutics, Inc. (CIK: 0001359931) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TARA's EPS?
Protara Therapeutics, Inc. has a diluted EPS of $-1.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TARA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Protara Therapeutics, Inc. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TARA stock overvalued or undervalued?
Valuation metrics for TARA: ROE of -29.2% (sector avg: 15%), net margin of -32,269.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TARA stock in 2026?
Our dual AI analysis gives Protara Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TARA's free cash flow?
Protara Therapeutics, Inc.'s operating cash flow is $-56.4M, with capital expenditures of $94.0K. FCF margin is -31,718.5%.
How does TARA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -32,269.1% (avg: 12%), ROE -29.2% (avg: 15%), current ratio 14.58 (avg: 2).